Details of the Drug
General Information of Drug (ID: DMKZIES)
Drug Name |
Chloroethylclonidine
|
||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Synonyms |
Chloroethylclonidine; Chlorethylclonidine; UNII-3X825O680H; N-(2,6-Dichloro-4-(((2-chloroethyl)methylamino)methyl)phenyl)-4,5-dihydro-1H-imidazol-2-amine; 3X825O680H; 98086-36-3; 1h-imidazol-2-amine, n-[2,6-dichloro-4-[[(2-chloroethyl)methylamino]methyl]phenyl]-4,5-dihydro-; 1H-Imidazol-2-amine, N-(2,6-dichloro-4-(((2-chloroethyl)methylamino)methyl)phenyl)-4,5-dihydro-; Lopac-B-003; AC1Q3UQS; AC1L2XTB; Lopac0_000195; C11H12Cl3N3; SCHEMBL4107963; CHEMBL326967; SCHEMBL18154646; CTK3I7576; PDSP2_000070; ZINC27089957
|
||||||||||||||||||||||
Indication |
|
||||||||||||||||||||||
Drug Type |
Small molecular drug
|
||||||||||||||||||||||
Structure | |||||||||||||||||||||||
3D MOL | 2D MOL | ||||||||||||||||||||||
#Ro5 Violations (Lipinski): 0 | Molecular Weight (mw) | 335.7 | |||||||||||||||||||||
Logarithm of the Partition Coefficient (xlogp) | 2 | ||||||||||||||||||||||
Rotatable Bond Count (rotbonds) | 6 | ||||||||||||||||||||||
Hydrogen Bond Donor Count (hbonddonor) | 2 | ||||||||||||||||||||||
Hydrogen Bond Acceptor Count (hbondacc) | 2 | ||||||||||||||||||||||
Chemical Identifiers |
|
||||||||||||||||||||||
Cross-matching ID | |||||||||||||||||||||||
Molecular Interaction Atlas of This Drug
Drug Therapeutic Target (DTT) |
|
|||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Molecular Interaction Atlas (MIA) | ||||||||||||||||||||||||||||||||
Molecular Expression Atlas of This Drug
The Studied Disease | Discovery agent | |||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
ICD Disease Classification | N.A. | |||||||||||||||||||||||
|
||||||||||||||||||||||||
Molecular Expression Atlas (MEA) | ||||||||||||||||||||||||